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Purpose: To investigate the predictive factors of unfavorable prostate cancer in Korean men who underwent radical prostatectomy 
but eligible for active surveillance according to Epstein criteria. 
Methods: We retrospectively reviewed the medical records of 2,036 patients who underwent radical prostatectomy for prostate 
cancer between 1994 and 2011. Among these, 233 patients were eligible for active surveillance based on Epstein criteria. Unfavorable 
prostate cancer was defined as pathologic Gleason sum ≥7 or non–organ-confined disease. We investigated pathologic outcomes 
and predictive factors for unfavorable prostate cancer. 
Results: Of 233 cases, 91 patients (39.1%) were pathologic Gleason sum ≥7, 11 (4.7%) had extracapsular extension, and three (1.3%) 
had seminal vesicle invasion. Ninety-eight patients (42.1%) had unfavorable prostate cancer. When comparing clinically insignificant 
and significant prostate cancer, there were significant differences in mean age (P=0.007), prostate volume (P=0.021), prostate-specific 
antigen (PSA) density (P=0.03), maximum tumor volume in biopsy core (P<0.001), and rate of two positive cores (P=0.001). On mul-
tivariate analysis, age (P=0.015), PSA density (P=0.017) and two positive cores (P=0.001) were independent predictive factors for 
unfavorable prostate cancer. 
Conclusions: A significant proportion of patients who were candidates for active surveillance had unfavorable prostate cancer. Age, 
PSA density, and two positive cores were independent significant predictive factors for unfavorable prostate cancer. These factors 
should be considered when performing active surveillance.
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INTRODUCTION
Low-risk prostate cancer is a very indolent disease with a 
limited impact on life expectancy. The Scandinavian Prostate 
Cancer Group Study Number 4 reported that among men in 
the low-risk group, radical prostatectomy did not significantly 
reduce the rate of death from prostate cancer [1]. The Prostate 
Cancer Intervention versus Observation Trial compared the 
outcome of prostatectomy and observation and showed no 
difference in cancer-specific survival among men with low-
risk cancers [2]. These studies advocate the use of active sur-
veillance (AS) and AS is now considered a viable treatment 
option for low-risk prostate cancer. However, these data are 
not directly applicable to Asian men. Center et al. [3] reported 
international variation in prostate cancer incidence and mor-
tality rates. Prostate cancer incidence rates in Asia are among 
the lowest worldwide but the annual percent change in inci-
dence in the Republic of Korea was 13.8%. Byun et al. [4] re-
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2. Statistical analyses
Continuous variables were compared using the Mann-Whit-
ney U-test, and categorical variables were compared using 
the chi-square test. Potential predictors for unfavorable pros-
tate cancer were analyzed by univariable and multivariable 
logistic regression models. For logistic regression analysis 
PSA density was replaced with the transformed value of PSA 
density × 10 (PSAD10). The 5-year BCR-free survival rate was 
estimated using the Kaplan-Meier method and compared 
using the Log-rank test. All P-values were two-sided, and a 
value of P< 0.05 was considered statistically significant. All 
data analyses were performed with IBM SPSS ver. 19.0 (IBM 
Co., Armonk, NY, USA).
3. Ethics statement
The study protocol was approved by the Institutional Review 
Board of Samsung Medical Center (IRB No. 2012-07-068). In-
formed consent was waived by the IRB. 
RESULTS
Table 1 shows the clinical characteristics of 233 patients in-
cluded in this study. Majority of enrolled patients (222/233, 
95.7%) underwent radical prostatectomy after January 2005. 
The mean age at the time of surgery was 64.6 years (range, 
43–73 years). Mean PSA level and PSA density were 4.3 ng/
ported that Korean men with prostate cancer now have better 
clinicopathologic parameters than previously. Nonetheless, 
they showed worse pathologic features than Western men: 
approximately 50% of Western men had a pathologic Gleason 
sum of 6 or lower compared with only approximately 30% of 
Korean men. Thus, although AS is a treatment option for low-
risk prostate cancer in the western world it is doubtful whether 
this applies to Asian men. We analyzed the pathologic features 
of possible candidates for AS among Korean prostate cancer 
patients and investigated the predictive factors of unfavorable 
prostate cancer. 
MATERIALS AND METHODS
1. Patients
We retrospectively reviewed the medical records of 2,036 
patients who underwent radical prostatectomy for prostate 
cancer at Samsung Medical Center between September 1995 
and December 2011. Patients who underwent neoadjuvant 
therapy and those with no biopsy slide or incomplete data 
were excluded. In total 233 patients fulfilled the inclusion 
criteria for AS defined by Carter et al. [5], which are defined 
as clinically localized (T1) disease, prostate-specific antigen 
(PSA) density ≤ 0.15 ng/mL2, Gleason score ≤ 6, fewer than 
three cores containing prostate cancer, and lower than 50% 
cancer involvement in any core [6]. We compared the patho-
logical findings between prostate biopsies and specimens 
after radical prostatectomy. 
 Three different radical prostatectomy methods were used: 
38.6% of patients (90/233) had open radical prostatectomy, 
52.8% (123/233) had robot-assisted laparoscopic prostatec-
tomy, and 8.6% (20/233) had laparoscopic radical prosta-
tectomy. Neurovascular bundle saving was done in 78.5% 
(183/233). Unfavorable prostate cancer was defined as patho-
logic Gleason score sum ≥7 or non–organ-confined disease 
(extracapsular extension or seminal vesicle invasion) after rad-
ical prostatectomy. Our institutional pathologists reviewed all 
biopsy slides from other institutions. The percentage of tumor 
volume in each biopsy core was measured. Prostate volume 
was determined by transrectal ultrasound or magnetic reso-
nance imaging using the formula π/6×width×height×length. 
PSA density was calculated as preoperative PSA divided by 
prostate volume. Biochemical recurrence (BCR) was defined 
as an initial serum PSA level ≥0.2 ng/mL with a second con-
firmatory serum PSA level >0.2 ng/mL [7]. We investigated 
pathologic outcomes and predictive factors for unfavorable 
prostate cancer. Clinical and pathologic staging was assigned 
according to the 2002 TNM staging system. 
Table 1. Clinical and needle biopsy characteristics of patients 
Characteristic Value
No. of patients 233
Age (yr) 64.6±6.2 (43–77)
Body mass index (kg/m2) 24.6±2.7 (17.5–39.4)
PSA (ng/mL) 4.3±1.5 (0.91–10.80)
Prostate volume (mL) 45.1±19.4 (18.4–173.0)
PSA density (ng/mL2) 0.10±0.03 (0.031–0.149)
Maximum tumor volume in biopsy core (%) 24.6±12.5 (1–50)
No. of biopsy cores
  <10 24 (10.3)
  ≥10 209 (89.7)
Biopsy Gleason score
  <6 6 (2.6)
  6 227 (97.4)
No. of positive cores
   1 168 (72.1)
   2 65 (27.9)
Laterality of biopsy cores
  Unilateral 212 (91.0)
  Bilateral 21 (9.0)
Values are presented as mean±standard deviation (range) or number 
(%).
PSA, prostate specific antigen. 
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 When comparing favorable and unfavorable prostate 
cancer, there were significant differences in mean age (63.7 
vs. 65.9, P= 0.007), prostate volume (47.1 mL vs. 42.2 mL, P=  
0.021), PSA density (0.096 ng/mL2 vs. 0.104 ng/mL2, P= 0.03), 
maximum tumor volume in biopsy core (11.6% vs. 18.3%, P<  
0.001), and percentage of patients with two positive cores 
(19.3% vs. 39.8%, P= 0.001) (Table 3). There was no difference 
in laterality of positive biopsy cores. The patients who had 
family history of prostate cancer were 4.7% (11/223) and there 
was no difference between favorable and unfavorable pros-
tate cancer (3.7% vs. 6.1%, P= 0.534). 
 We used logistic regression analysis to identify predictive 
factors for unfavorable prostate cancer. On univariable analy-
sis, age (odds ratio [OR], 1.06; 95% confidence interval [CI], 
1.02–1.11; P=0.009), PSA density (OR, 2.88; 95% CI, 1.11–7.43; 
P=0.029), maximum tumor volume (OR, 1.05; 95% CI, 1.02–
1.07; P<0.001), and two positive cores (OR, 2.77; 95% CI, 1.54–
4.99; P=0.001) were predictors of unfavorable prostate cancer. 
On multivariable analysis, age (OR, 1.06; 95% CI, 1.01–1.11; 
P=0.015), PSA density (OR, 3.41; 95% CI, 1.25–9.30; P=0.017), 
and two positive cores (OR. 2.83; 95% CI; 1.54–5.20; P=0.001) 
were independent predictive factors for unfavorable prostate 
cancer (Table 4). The median follow-up was 30 months and 
the 5-year BCR-free survival rates were estimated to be 96.8% 
for favorable prostate cancer and 98% for unfavorable prostate 
cancer, with no significant difference (P=0.734).  
mL and 0.10 ng/mL2 respectively. All patients had a mini-
mum of six biopsy cores and 89.7% had 10 or more biopsy 
cores. Most patients (72.1%) had one positive core, 27.9% had 
two positive cores, and 9.0% had positive cores on both sides 
of the prostate. 
 Table 2 shows the clinicopathologic findings after radical 
prostatectomy. Ninety-eight of 233 patients (42.1%) had un-
favorable prostate cancer. Among these, 91 patients (39.1%) 
had pathologic Gleason score sum ≥ 7, 11 (4.7%) had extra-
capsular extension, and three (1.3%) had seminal vesicle 
invasion. One patient (0.4%) had Gleason score sum of 9. We 
did lymph node dissection in 48 patients (20.6%) and no pa-
tient had a positive pelvic lymph node. 
Table 2. Postprostatectomy pathologic outcomes 
Variable No. (%)
Unfavorable prostate cancer 98 (42.1)
  Pathologic up-staging 14 (6.0)
     Extracapsular extension 11 (4.7)
     Seminal vesicle invasion 3 (1.3)
  Pathologic up-grading 91 (39.1)
    3+4 83 (35.6)
    4+3 7 (3.0)
    4+5 1 (0.4)
Positive surgical margin 11 (4.7)
Lymph node invasion
  Negative 48 (20.6)
  Not performed 185 (79.4)
Table 3. Comparison of preoperative variables between patients with favorable and unfavorable prostate cancer  
Variable Favorable PCa Unfavorable PCa P-value
No. of patients 135 98
Age (yr) 63.7 (49–77) 65.9 (43–77) 0.007
Body mass index (kg/m2) 24.6 (17.5–39.4) 24.7 (18.3–30.1) 0.459
PSA (ng/mL) 4.3 (0.91–9.00) 4.2 (0.93–10.80) 0.606
Prostate volume (mL) 47.1 (18.4–173.0) 42.2 (20.0–113.0) 0.021
PSA density (ng/mL2) 0.096 (0.040–0.148) 0.104 (0.031–0.149) 0.030
Maximum tumor volume in biopsy core (%) 11.6 (1.0–50.0) 18.3 (2.0–50.0) <0.001
No. of biopsy cores 0.967
  <10 14 (10.4) 10 (10.2)
  ≥10 121 (89.6) 88 (89.8)
Biopsy Gleason score 1.000
  <6 4 (3.0) 2 (2.0)
  6 131 (97.0) 96 (98.0)
No. of positive cores 0.001
  1 109 (89.7) 59 (60.2)
  2 26 (19.3) 39 (39.8)
Laterality of biopsy cores 0.142
  Unilateral 126 (93.3) 86 (87.8)
  Bilateral 9 (6.7) 12 (12.2)
Values are presented as mean (range) or number (%).
PCa, prostate cancer; PSA, prostate specific antigen.   
Vol. 2 / No. 2 / June 2014
73
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14042
DISCUSSION
Widespread use of PSA screening has increased detection 
rates of low-risk prostate cancer. Although screening has 
resulted in a significant decrease in prostate cancer mortal-
ity [8], it has also brought the new problems of overdiagnosis 
and overtreatment. The cost of diagnosis and treatment for 
potentially nonharmful disease is another problem. A recent 
report showed no difference in survival between expectant 
treatment and radical prostatectomy [2]. These findings have 
resulted in increased use of AS. AS has many advantages in-
cluding avoidance of side effects of definite therapy or unnec-
essary treatment of indolent cancers, retained quality of life, 
and decreased treatment costs. However, it also has several 
disadvantages including the possibility of missing the chance 
of cure, possible cancer progression, and increased anxiety 
over untreated cancers. Therefore, patient selection criteria 
are a critical aspect of successful AS. Many studies are being 
conducted and many contemporary AS criteria are available. 
In a meta-analysis of conservative management of clinically 
localized prostate cancer, Chodak et al. [9] reported that the 
10-year cancer-specific survival rate was 87% for low-grade 
prostate cancer and 81% for metastasis-free survival. How-
ever, their study reported long-term results of conservative 
management and the concept of AS is different. Reports of 
AS studies have a relatively short follow-up duration. Klotz et 
al. [10] reported long-term results of AS of 450 patients with a 
median follow-up of 6.8 years (1 to 13 years). Overall survival 
was 78.6% and the 10-year prostate cancer actuarial survival 
was 97.2%. Thirty percent of the patients were offered defini-
tive therapy, and 72% and 62% of patients were maintained 
on AS at 5 and 10 years respectively from the beginning of the 
study. Carter et al. [5] reported results of AS of 407 men: 59% 
remained on AS at a median follow-up of 3.4 years, 25% un-
derwent curative intervention, 3% were lost to follow-up, and 
11% withdrew from the program. Other studies on AS gen-
erally showed that 30% of patients receive curative therapy 
and cancer-specific mortality was low during 5 to 10 years of 
follow-up. However, these data are not conclusive and the 
studies were conducted in western populations thus their di-
rect application to Asian men may be inappropriate. 
 Compared with western patients, a higher proportion of Ko-
rean prostate cancer patients have high-grade disease. Song 
et al. [11] reported that more than 60% of American men have 
Gleason scores of 6 or lower, whereas 58.8% of Korean men 
have Gleason scores of 7 or greater. Furthermore, 50% of Ko-
rean patients with PSA level<4.0 ng/mL and 56.4% of patients 
with PSA level between 4.1 and 10.0 ng/mL have Gleason 
scores of 7 or greater. Similar results were reported in other 
Asian countries: 46.7% of Chinese men (57/122) and 56.2% 
of Japanese men (100/178) had Gleason score of 7 or greater 
in radical prostatectomy specimens. Lee et al. [12] analyzed 
131 Korean men who met the Epstein criteria and underwent 
prostatectomy. Of these, 30.5% (40/131) had pathologically 
unfavorable prostate cancer, defined as either Gleason sum 7 
or non–organ-confined disease. In contrast, Jeldres et al. [13] 
reported a similar study with European men in which 24% 
(88/366) had unfavorable pathologic outcomes. Analysis of 
the CaPSURE database (UCSF, Urology Outcomes Research 
Group and TAP Pharmaceutical Products, Inc., Lake Forest, IL, 
USA) showed that 24% of men (30/125) who met the Epstein 
criteria had pathologic upstaging or upgrading [14]. Our data 
showed that 42.1% (98/233) had pathologically unfavorable 
prostate cancer. These differences between western series and 
Korean series may be due to different PSA screening rates or 
differences in intrinsic cancer biology. 
 Similar studies conducted in Europe or the United States 
showed a higher rate of pathologic upgrading. Mufarrij et al. 
[15] reported 205 men who met the Epstein criteria, among 
which 45.9% showed pathologic upgrading to Gleason score 
7 or greater, and Kane et al. [16] reported an upgrading rate of 
36%. However, these studies did not report the total number 
of biopsy cores among the inclusion criteria and the tumor 
volume in biopsy cores. Freedland et al. [17] reported that 
42% of patients had pathologic upgrading from Gleason 6 to 7 
and patients with more than eight biopsy cores had a signifi-
cantly lower rate of upgrading (OR, 0.62; 95% CI, 0.43–0.89; 
Table 4. Logistic regression analysis for favorable prostate can-
cer 
Variable
Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Age 1.06 1.02–1.11 0.009 1.06 1.01–1.11 0.015
BMI 1.01 0.92–1.11 0.834
PSA 0.93 0.79–1.11 0.432
Prostate volume 0.99 0.97–1.00 0.061
PSAD10 2.88 1.11–7.43 0.029 3.41 1.25–9.30 0.017
Maximum tumor
  volume
1.05 1.02–1.07 <0.001
No. of biopsy
  cores
1.02 0.43–2.40 0.967
Biopsy Gleason
  score
1.47 0.24–8.17 0.663
No. of positive
  cores
2.77 1.54–4.99 0.001 2.83 1.54–5.20 0.001
Laterality of 
  biopsy cores
1.95 0.79–4.84 0.148
OR, odds ratio; CI, confidence interval; BMI, body mass index; PSA, pros-
tate specific antigen; PSAD10, PSA density ×10.
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P= 0.01). Abouassaly et al. [18] also showed that a high num-
ber of biopsy cores are related to reduced Gleason upgrading. 
Our study also included men with fewer than 10 biopsy cores, 
but they represented only about 10% of the population and 
3% (7/233) had fewer than eight biopsy cores. 
 Many studies have been conducted to analyze the patholog-
ic outcomes of radical prostatectomy in possible candidates for 
AS. However, most of these studies were conducted in Western 
countries and only a few were performed in Asia. Few studies 
suggested predictive factors for unfavorable disease. Beauval 
et al. [19] showed that prostate volume was significantly pre-
dictive for insignificant prostate cancer. Our study showed that 
older age, PSA density, and two positive cores were indepen-
dent predictors of unfavorable disease. Although these results 
will not alter the criteria for AS, they might help in the decision 
making process for patients considering AS. Further studies 
based on a large population might suggest different criteria for 
AS. 
 In the current study, the 5-year BCR-free survival rate was 
estimated to be 97.3%, compared with 92% to 100% in other 
similar studies [14,15,19,20]. Despite the high proportion of 
pathologic upgrading, BCR-free survival rates were high. This 
could be because the data are based on low-risk prostate can-
cer and a favorable BCR rate was the natural result, or because 
of the relatively short follow-up period (approximately 2.5 
years). Other studies showed no significant difference in BCR 
rate using different inclusion criteria [21,22]. Iremashvili et al. 
[21] compared pathologic cancer characteristics in patients 
grouped according to five different contemporary AS criteria 
and showed no significant difference in BCR-free survival. 
Ploussard et al. [22] also compared pathologic findings of can-
didates for AS who were divided into three different groups 
based on biopsy criteria and showed no significant difference 
in BCR-free survival rates. However, because these studies 
had short follow-up durations, further investigations are nec-
essary to reveal the relationship between different AS criteria 
and BCR-free survival. In addition, Thaxton et al. [23] reported 
that a biopsy Gleason score greater than 6 had a 2.74- to 3.19-
fold increased hazard ratio for biochemical progression. 
 This study has several limitations. First, this was a retro-
spective study performed at a single center. Second, there 
was heterogeneity in the biopsy cores and no cutoff values. 
This study included men with six or more biopsy cores but 
89.7% of them (209/233) had 10 or more biopsy cores. When 
analyzed separately, older age, PSA density, and two positive 
cores were independent predictors of unfavorable disease. 
The relatively short follow-up duration is another limitation 
and long-term pathologic data are required. 
 In conclusion, AS is a promising treatment option for low-
risk prostate cancer patients because it avoids overtreatment 
or complications of prostatectomy or radiation therapy but 
it is not directly applicable to Korean men. Further definitive 
studies are required and stricter criteria should be established. 
Our study reported the rates of pathologic features or upgrad-
ing in Korean patients and suggested predictive factors of 
unfavorable prostate cancer. Our findings could provide guid-
ance when deciding whether to perform AS instead of other 
treatment options. 
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